No stone unturned by Petsko, Gregory A
Last month, I wrote about what I consider to be one of 
the most serious problems facing the life sciences in the 
age  of  genomics:  the  increasing  polarization  between 
those who do what they call ‘basic research’ and those 
who  do  what  is  termed  ‘translational  research’  [http://
genomebiology.com/2010/11/2/107].  I  argued  that  we 
have  created  this  problem  ourselves  by  accepting  this 
divisive terminology and using it in everyday discourse. 
And I asserted that we should abandon, forever, what I 
think is an artificial and inaccurate distinction.
But such a change raises a potential problem. Support 
for what we will no longer call basic research has, for 
quite some time, piggybacked on the support for what we 
will no longer call translational research, which was what 
scientific leaders presented to governments and laypeople 
as  the  raison  d’etre  for  public  support  of  biomedical 
research.  Generally,  they  didn’t  talk  much  about  basic 
research at all, believing that the public wouldn’t under­
stand it very well and therefore wouldn’t support it. They 
understood its importance themselves, so they paid for it, 
but they didn’t advertise it. National Institutes of Health 
(NIH) director Francis Collins’s now­famous remark that 
“We’re not the National Institutes of Basic Sciences” is 
but one example of this mentality. If we now are to talk 
about all research using the same language, how do we 
justify the support of projects that don’t have an obvious 
clinical relevance, and may never have one?
This problem is becoming more acute because we have 
oversold some big science projects in order to gain the 
huge financial support they require. The human genome 
sequencing  effort,  which  was  really  a  basic  research 
project, was presented as a faster route to diagnosis and 
cures for a host of diseases, although it typically takes 
decades for research results to lead to clinical advances. 
Congress and the public, having bought the original sales 
pitch, are now asking, “So where are the cures?”
Three articles in the 17 March issue of the Journal of 
the American Medical Association (JAMA) highlight this 
increasing impatience. They concern the War on Cancer, 
a huge increase in both funding and responsibilities for 
the US National Cancer Institute (one of the institutes 
that make up the National Institutes of Health) that was 
started by President Richard Nixon in 1971. Ignoring the 
fact  that  the  language  of  the  legislation  implied  that 
cancer was one disease, which it most assuredly is not, 
and  therefore  should  have  one  cure,  which  it  most 
assuredly does not, the war has led to $100 billion dollars 
in research funding in the past 40 years, much of which 
has  been  spent  on  ‘basic’  research  in  cellular  and 
developmental  biology.  Now,  as  Susan  Gapstur  and 
Michael Thun point out [1], the cancer war has become a 
lightning  rod,  even  for  some  who  support  its  goals. 
“Frustration about the pace of its progress,” they write, 
“has led some critics to dismiss advances that have been 
made,”  and  “nearly  1  in  2  men  and  more  than  1  in  3 
women will be diagnosed with cancer given the current 
lifespan.”  The  annual  cost  to  the  United  States  of  all 
cancers, as given by Elena Elkin and Peter Bach in an 
accompanying article [2], is more than $90 billion a year 
(by comparison, the entire NIH budget is just a little over 
$30  billion).  As  more  families  face  cancer­associated 
medical costs that can wipe out a lifetime of savings in a 
single year, the demand that scientists deliver on their 
promises is growing from a rumbling to a chorus.
Of  course,  there  have  been  many  successes  in  the 
cancer  war,  most  of  them  resulting  from  fundamental 
discoveries about how cell growth is regulated and how 
cancer starts. Miracle drugs have turned testicular cancer 
and  gastrointestinal  stromal  cancer  and  chronic 
myelogenous leukemia, to name but a few, into treatable 
diseases in many cases. But there are over 100 different 
forms of cancer, and most of them still have no cure if the 
disease is not caught at its earliest stages. Faced with this 
reality, the instinct of many scientific administrators and 
researchers is to make even more promises, and to push 
even  harder  for  more  applied  research.  Writing  in  the 
same issue of JAMA, John Niederhuber [3], the current 
Director of the National Cancer Institute, does exactly 
that: “To realize a future of personalized medicine, the 
translation of genomic and functional biology discoveries 
into clinical practice is essential.”
So you see what we’re up against. We should talk about 
research as a seamless whole, a continuum of effort that 
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human diseases. Yet in order to justify it to the public, we 
have created a distinction that could ultimately tear the 
biomedical community asunder. How do we make people 
understand  why  it  is  in  their  best  interest  for  us  to  do 
things that have no apparent connection to their concerns?
An old joke encapsulates the problem. A drunkard is 
looking for his lost car keys at night under a lamppost. A 
passerby  offers  to  help  and  asks  exactly  where  he  lost 
them.  “Over  there,”  he  replies,  pointing  off  into  the 
darkness. “But then, why are you looking for them here?” 
says  the  puzzled  samaritan.  The  drunkard  explains, 
“Because the light’s better here.”
If the only kind of research we do is based on what we 
already know, we are looking where we already have light. 
If  it  turns  out  that’s  where  the  keys  are,  fine.  But  we 
usually aren’t sure where the keys are, so we also need to 
go looking in the darkness. “Basic research” is the light 
that shines in that dark.
Now,  I  realize  that  basing  support  for  all  forms  of 
research on a joke may not be the most politically astute 
of ideas ­ although I bet it would be a pretty good tactic if 
you have to explain biomedical research to a gathering of 
laypeople. Besides, in this age of 10­second sound bites, 
we need something more immediately memorable, and 
digestible. But the metaphor of hunting for what is lost 
provides the answer.
The greatest reassurance we can offer people with life­
threatening or crippling illnesses is that we are leaving no 
stone unturned in our efforts to find them a treatment. If 
we only do research that applies discoveries we already 
have made, we are only looking under stones that have 
already been turned. That we must do, but if it’s all we do, 
it’s not enough. We also need to turn over new stones, 
because we have no idea where the answers lie. I think 
anyone  can  understand  that,  and  appreciate  it.  This 
metaphor  makes  clear  the  value,  and  continuity,  of  all 
forms of scientific research. And it allows us to discard 
the ‘basic’ and ‘translational’ dichotomy once and for all.
When I go onto the web site of the National Institutes 
of  Health  [http://www.nih.gov],  which  includes  the 
National  Institute  of  General  Medical  Science  (that’s 
‘Basic Sciences’, in fact), I notice that this gigantic human 
endeavor  has  no  motto  (it  says  “The  Nation’s  Medical 
Research Agency” as a subtitle, but any marketing expert 
would  turn  his  or  her  nose  up  at  such  a  dull  and 
unmemorable phrase). I think it needs one. It should be 
something  that  any  layperson  can  immediately  grasp, 
something that speaks to the dedication, commitment, 
passion,  and  effort  of  biomedical  scientists  to  do 
everything in our power to better their lives. It should be 
not  just  NIH’s  motto,  but  our  motto.  What  could  be 
better than “No Stone Unturned”.
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